Read Time:29 Second
Shares of Neuronetics Inc. gained 22.5% in premarket trading on Tuesday after the company said it received clearance from the Food and Drug Administration to market its transcranial magnetic stimulation system as a treatment for anxiety in adults with major depressive disorder. The system was previously cleared to treat obsessive-compulsive disorder. Neuronetics’ stock is down 18.4% this year, while the broader S&P 500 has declined 18.9%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0